stoxline Quote Chart Rank Option Currency Glossary
  
Brickell Biotech, Inc. (BBI)
2.35  0.05 (2.17%)    09-08 00:00
Open: 2.26
High: 2.37
Volume: 31,317
  
Pre. Close: 2.3
Low: 2.21
Market Cap: 7(M)
Technical analysis
2022-11-18 4:18:53 PM
Short term     
Mid term     
Targets 6-month :  2.76 1-year :  3.23
Resists First :  2.36 Second :  2.76
Pivot price 2.32
Supports First :  1.95 Second :  1.7
MAs MA(5) :  2.34 MA(20) :  2.23
MA(100) :  2.65 MA(250) :  7.21
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  96.2 D(3) :  96.2
RSI RSI(14): 63.4
52-week High :  18.94 Low :  0.11
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ BBI ] has closed below upper band by 43.3%. Bollinger Bands are 73.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 85 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 2.37 - 2.38 2.38 - 2.39
Low: 2.18 - 2.2 2.2 - 2.21
Close: 2.33 - 2.35 2.35 - 2.37
Company Description

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Headline News

Mon, 05 Dec 2022
Atopic Dermatitis Pipeline Appears Robust With 90+ Key - GlobeNewswire

Wed, 07 Sep 2022
Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics - GlobeNewswire

Tue, 28 Jun 2022
Brickell Biotech Inc (NASDAQ: BBI) Announces Dosing of First Subject with its BBI-02 - BP Journal

Wed, 04 May 2022
Troutman Pepper Advises Clinical Dermatology Company Botanix Pharmaceuticals in Acquisition of Sofpironium Bromide - Troutman Pepper

Tue, 19 Apr 2022
Has Brickell Biotech (BBI) Outpaced Other Medical Stocks This Year? - Yahoo Finance

Tue, 01 Feb 2022
The 10 Best Webull Stocks Under 5 Dollars To Buy For %currentmonth% %currentyear% - The Stock Dork

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Neutral
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 115 (M)
Held by Insiders 2.48e+006 (%)
Held by Institutions 1.3 (%)
Shares Short 108 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -4.062e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -8 %
Return on Assets (ttm) 486.2 %
Return on Equity (ttm) -85.2 %
Qtrly Rev. Growth 479000 %
Gross Profit (p.s.) 1076.09
Sales Per Share -430.47
EBITDA (p.s.) -6.7878e+007
Qtrly Earnings Growth -0.7 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -40 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow 4.37
Stock Dividends
Dividend 0
Forward Dividend 181260
Dividend Yield 0%
Dividend Pay Date 2019-09-02
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android